Charu Aggarwal, MD, MPH
Enriched profileLeslye M. Heisler Professor for Lung Cancer Excellence, University of Pennsylvania Perelman School of Medicine; Associate Director, Penn Center for Cancer Care Innovation (PC3I) · University of Pennsylvania Perelman School of Medicine
Charu Aggarwal is Leslye M. Heisler Professor for Lung Cancer Excellence, University of Pennsylvania Perelman School of Medicine; Associate Director, Penn Center for Cancer Care Innovation (PC3I) at University of Pennsylvania Perelman School of Medicine. OpenAlex indexes 429 publications with 16,193 citations (h-index 49); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Oct 2026
Overview
Updated 14 Oct 2026
Charu Aggarwal, MD, MPH, is Leslye M. Heisler Professor for Lung Cancer Excellence, University of Pennsylvania Perelman School of Medicine. The public record shows 429 publications with 16,193 citations (h-index 49), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 31 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 31 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 27 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 126.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
Sponsor: Charu Aggarwal
- Telehealth Based Synchronous Navigation to Improve Molecularly-Informed Care for Patients With Lung Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Industry payments
Updated 14 Oct 2026
31 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year202518 payments$35,054openpaymentsdata.cms.gov ↗
- AstraZeneca UK LimitedProgram year20258 payments$23,286openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20254 payments
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Phenothiazine100%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
113 congress contributions (2006–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 2449: Comparison of liquid versus solid tissue genomic profiling for the prediction of chemo-immunotherapy benefit in advanced NSCLC
AACR Annual Meeting
AACR2026Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer.
JCO precision oncology
Article2026 - Illusion of Comprehensive Testing in Non-Small Cell Lung Cancer: Why Coverage, Sensitivity, and Reporting Matter.
JCO oncology practice
Article2026
Most-cited works
by citation count (OpenAlex)- 01Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerArticle6,181 citations2015
- 02NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020Article956 citations2019
- 03
- 04
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medifind.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cms.gov ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cms.gov ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
- Associate Editor
ASCO Post Editorial Board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Past Chair
ASCO Cancer Communications Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - National Substudy Chair
Lung Cancer Master Protocol (Lung-Map)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Active Member
Eastern Cooperative Oncology Group (ECOG)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Secondary affiliations
appointments beyond the home institution- Abramson Cancer Center
University of Pennsylvania
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →www3.pennmedicine.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julio Chirinos, MD
University of Pennsylvania Perelman School of Medicine
Michael Rickels, MD
University of Pennsylvania Perelman School of Medicine
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center